Macroaxis Story

Macroaxis News
  
By Vlad Skutelnik

September 14, 2019

Today article will analyze 8 Marijuana equities to potentially sell in October 2019. I will specifically cover the following equities: BLUE LINE PROTECTION GROUP INC, ABATTIS BIOCEUTICALS CORP, ENERTOPIA CORPORATION, AERO GROW INTERNATIONAL INC, CGROWTH CAPITAL INC, GENERAL CANNABIS CORP, CANNAGROW HOLDINGS INC, and CV SCIENCES INC
8 Marijuana stocks to get rid of in October 2019

This list of potential positions covers Small and Mid-sized companies with exposure to distribution of Marijuana. Small and mid-cap equities that are involved in production and delivery of Marijuana products. This theme is designed for investors that are willing to accept higher levels of market risk inherited by Marijuana production in the United States in USA. Please note, we provide buy hold or sell recommendation only in the context of selected investment horizon assuming investor has average attitude towards taking risk. Please also consider using Portfolio Positions Ratings and Equity Ratings tools to further calibrate your research.


BLUE LINE PROTECTION GROUP INC (BLPG)

The company has Profit Margin (PM) of (61.5) % which may suggest that it does not properly executes on its current pricing strategies or is unable to control all of the operational costs. This is way below average. Similarly, it shows Operating Margin (OM) of (21.53) % which suggests for every $100 dollars of sales it generated a net operating loss of -0.22. The entity currently falls under 'Nano-Cap' category with current market capitalization of 374.05 K. BLUE LINE seems to be overvalued based on Macroaxis valuation methodology. This module approximates value of BLUE LINE PROTECTION from analyzing the firm fundamentals such as Return On Equity of (38.00)  and Profit Margin of (61.50)  as well as examining its technical indicators and Probability Of Bankruptcy. In general, we favor to go long with undervalued instruments and to trade away overvalued instruments since at some point future time assets prices and their ongoing real values will blend. BLUE LINE seems to be overvalued based on Macroaxis valuation methodology. This module approximates value of BLUE LINE PROTECTION from analyzing the firm fundamentals such as Return On Equity of (38.00)  and Profit Margin of (61.50)  as well as examining its technical indicators and Probability Of Bankruptcy. In general, we favor to go long with undervalued instruments and to trade away overvalued instruments since at some point future time assets prices and their ongoing real values will blend.

ABATTIS BIOCEUTICALS CORP (ATTBF)

The company has return on total asset (ROA) of 6.69 % which means that it generated profit of $6.69 on every $100 spent on asset. This is normal as compared to the sector avarege. Similarly, it shows return on equity (ROE) of (139.36) % meaning that it generated substantial loss on money invested by shareholders. This firm currently falls under 'Nano-Cap' category with current market capitalization of 8.41 M. ABATTIS BIOCEUTICALS seems to be fairly valued based on Macroaxis valuation methodology. This module approximates value of ABATTIS BIOCEUTICALS CORP from examining the entity fundamentals such as Return On Asset of 6.69  and Price to Book of 0.14  as well as evaluating its technical indicators and Probability Of Bankruptcy. In general, we favor to invest in undervalued equities and to trade away overvalued equities since at some future date instruments prices and their ongoing real values will grow together.

ENERTOPIA CORPORATION (ENRT)

The company reported previous year revenue of 57. Net Loss for the year was (443.97 K) with profit before overhead, payroll, taxes, and interest of 5.98 K. The entity currently falls under 'Nano-Cap' category with current market capitalization of 987.91 K. ENERTOPIA CORPORATION seems to be overvalued based on Macroaxis valuation methodology. This module computes value of ENERTOPIA CORPORATION from examining the firm fundamentals such as Price to Earning of (5.00)  and Shares Outstanding of 127.47 M as well as evaluating its technical indicators and Probability Of Bankruptcy. In general, we advise to go long with undervalued instruments and to sell out overvalued instruments since in the future assets prices and their ongoing real values will submerge.

AERO GROW INTERNATIONAL INC (AERO)

About 83.0% of the company shares are held by company insiders. The book value of The entity was presently reported as 0.33. The company has Price/Earnings (P/E) ratio of 184.17. The entity recorded loss per share of 0.02. The entity last dividend was issued on 2016-12-16. The firm had 1:100 split on 2012-10-17. This firm currently falls under 'Micro-Cap' category with current market capitalization of 27.46 M. AERO GROW INTERNATIONAL shows prevailing Real Value of $0.8211 per share. The current price of the firm is $0.85. the firm appears to be fairly valued. This module approximates value of AERO GROW INTERNATIONAL from reviewing the firm fundamentals such as Return On Equity of (6.08)  and Profit Margin of (2.04)  as well as analyzing its technical indicators and Probability Of Bankruptcy. In general, we favor to go long with undervalued instruments and to trade away overvalued instruments since in the future assets prices and their ongoing real values will blend.

CGROWTH CAPITAL INC (CGRA)

The company has price-to-book (P/B) ratio of 0.41. Some equities with similar Price to Book (P/B) outperform the market in the long run. The entity recorded loss per share of 0.0. The entity had not issued any dividends in recent years. The firm had 1:200 split on 2010-02-23. This firm currently falls under 'Nano-Cap' category with current market capitalization of 59.28 K. CGROWTH CAPITAL seems to be undervalued based on Macroaxis valuation methodology. This module approximates value of CGROWTH CAPITAL INC from reviewing the firm fundamentals such as Price to Earning of (11.10)  and Return On Asset of (758.28)  as well as analyzing its technical indicators and Probability Of Bankruptcy. In general, we favor to go long with undervalued instruments and to trade away overvalued instruments since in the future assets prices and their ongoing real values will blend.

GENERAL CANNABIS CORP (CANN)

The company has return on total asset (ROA) of (80.86) % which means that it has lost $80.86 on every $100 spent on asset. This is way below average. Similarly, it shows return on stockholders equity (ROE) of (330.43) % meaning that it created substantial loss on money invested by shareholders. The firm currently falls under 'Micro-Cap' category with current market capitalization of 24 M.

CANNAGROW HOLDINGS INC (CGRW)

The company has Profit Margin (PM) of (119.25) % which may suggest that it does not properly executes on its current pricing strategies or is unable to control all of the operational costs. This is way below average. Similarly, it shows Operating Margin (OM) of (85.37) % which suggests for every $100 dollars of sales it generated a net operating loss of -0.85. The entity currently falls under 'Micro-Cap' category with current market capitalization of 20.25 M. CANNAGROW HOLDINGS seems to be fairly valued based on Macroaxis valuation methodology. This module approximates value of CANNAGROW HOLDINGS INC from examining the entity fundamentals such as Profit Margin of (119.25) , Shares Outstanding of 101.27 M and Operating Margin of (85.37)  as well as evaluating its technical indicators and Probability Of Bankruptcy. In general, we favor to go long with undervalued instruments and to trade away overvalued instruments since in the future assets prices and their ongoing real values will blend. CANNAGROW HOLDINGS seems to be fairly valued based on Macroaxis valuation methodology. This module approximates value of CANNAGROW HOLDINGS INC from examining the entity fundamentals such as Profit Margin of (119.25) , Shares Outstanding of 101.27 M and Operating Margin of (85.37)  as well as evaluating its technical indicators and Probability Of Bankruptcy. In general, we favor to go long with undervalued instruments and to trade away overvalued instruments since in the future assets prices and their ongoing real values will blend.

CV SCIENCES INC (CVSI)

The company has Profit Margin (PM) of (3.29) % which may suggest that it does not properly executes on its current pricing strategies or is unable to control all of the operational costs. This is way below average. Similarly, it shows Operating Margin (OM) of (3.09) % which suggests for every $100 dollars of sales it generated a net operating loss of -0.03. The firm currently falls under 'Small-Cap' category with current market capitalization of 195.49 M. CV SCIENCES competes with Allergan Plc, MERCK KGAA, SHANGHAI FOSUN, Catalent, IPSEN, Mylan NV, Guangzhou Baiyunshan, EISAI CO, and TAKEDA PHARMACEUTICAL. CV Sciences, Inc. operates in consumer products and drug development businesses. CV Sciences, Inc. was founded in 2010 and is based in San Diego, California. CV SCIENCES operates under Drug Manufacturers - Specialty Generic classification in USA and is traded on BATS Exchange. It employs 78 people.

Current 8 Marijuana Recommendations

Competition Technical Indicators

Mean
Deviation
Jensen
Alpha
Sortino
Ratio
Treynor
Ratio
Semi
Deviation
Information
Ratio
Expected
Shortfall
Potential
Upside
Value
At Risk
Maximum
Drawdown
 0.51  0.12  0.25  0.32  0.37  0.23 (0.61)  1.12 (0.71)  2.57 
 1.02  0.15  0.07  0.33  1.29  0.11 (1.54)  2.81 (2.67)  8.86 
 1.36 (0.03)  0.00 (0.11)  0.00 (0.0034)  0.00  5.01 (3.57)  26.31 
 1.42 (0.13)  0.00 (0.15)  0.00 (0.07)  0.00  2.66 (2.94)  7.13 
 1.46 (0.28)  0.00 (3.89)  0.00 (0.11)  0.00  3.02 (4.25)  10.41 
 2.26  0.13  0.04  0.04  2.73  0.0349 (2.49)  3.56 (4.46)  21.09 
 0.53 (0.29)  0.00  4.26  0.00 (0.16)  0.00  0.00  0.00  11.54 
 0.47 (0.25)  0.00  4.32  0.00 (0.19)  0.00  0.00 (1.32)  8.80 
 1.27 (0.01)  0.01  1.17  1.61  0.01 (2.09)  4.35 (2.88)  13.82 

About Contributor

Vlad Skutelnik
   Vlad Skutelnik is a Macroaxis Contributor. Vlad covers stocks, funds, cryptocurrencies, and ETFs that are traded in North America focusing primarily on fundamentals, valuation and market volatility. He has many years of experience in fintech, predictive investment analytics, and risk management. View Profile
This story should be regarded as informational only and should not be considered as solicitation to sell or buy any financial products. Macroaxis does not express any opinion as to the present or future value of any investments referred to in this post. This post may not be reproduced without the consent of Macroaxis LLC. Macroaxis LLC and Vlad Skutelnik do not own shares of Macroaxis. Please refer to our Terms of Use for any information regarding our disclosure principles.

Did you try this?

Run Theme Ratings Now

   

Theme Ratings

Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance
All  Next Launch Module
See also Stocks Correlation. Please also try Transaction History module to view history of all your transactions and understand their impact on performance.
Search macroaxis.com